Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.52
AMED's Cash-to-Debt is ranked lower than
53% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 0.40 vs. AMED: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
AMED' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.37 Max: N/A
Current: 0.52
Equity-to-Asset 0.64
AMED's Equity-to-Asset is ranked higher than
70% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. AMED: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
AMED' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.31  Med: 0.55 Max: 1
Current: 0.64
-0.31
1
Interest Coverage 13.95
AMED's Interest Coverage is ranked higher than
58% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.17 vs. AMED: 13.95 )
Ranked among companies with meaningful Interest Coverage only.
AMED' s Interest Coverage Range Over the Past 10 Years
Min: 2.93  Med: 15.44 Max: 115.64
Current: 13.95
2.93
115.64
Piotroski F-Score: 6
Altman Z-Score: 6.69
Beneish M-Score: -2.61
WACC vs ROIC
11.44%
8.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 4.90
AMED's Operating Margin % is ranked lower than
69% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. AMED: 4.90 )
Ranked among companies with meaningful Operating Margin % only.
AMED' s Operating Margin % Range Over the Past 10 Years
Min: -33.08  Med: 3 Max: 15.25
Current: 4.9
-33.08
15.25
Net Margin % 3.16
AMED's Net Margin % is ranked lower than
65% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 4.84 vs. AMED: 3.16 )
Ranked among companies with meaningful Net Margin % only.
AMED' s Net Margin % Range Over the Past 10 Years
Min: -26.96  Med: 1.83 Max: 9.33
Current: 3.16
-26.96
9.33
ROE % 10.38
AMED's ROE % is ranked lower than
56% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 9.89 vs. AMED: 10.38 )
Ranked among companies with meaningful ROE % only.
AMED' s ROE % Range Over the Past 10 Years
Min: -54.77  Med: 5.95 Max: 20.95
Current: 10.38
-54.77
20.95
ROA % 6.36
AMED's ROA % is ranked higher than
54% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 4.66 vs. AMED: 6.36 )
Ranked among companies with meaningful ROA % only.
AMED' s ROA % Range Over the Past 10 Years
Min: -35.44  Med: 3.55 Max: 12.39
Current: 6.36
-35.44
12.39
ROC (Joel Greenblatt) % 169.59
AMED's ROC (Joel Greenblatt) % is ranked higher than
91% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. AMED: 169.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMED' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -326.21  Med: 77.02 Max: 233.27
Current: 169.59
-326.21
233.27
3-Year Revenue Growth Rate 2.10
AMED's 3-Year Revenue Growth Rate is ranked lower than
75% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. AMED: 2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMED' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -26.1  Med: 6.7 Max: 47.3
Current: 2.1
-26.1
47.3
GuruFocus has detected 4 Warning Signs with Amedisys Inc $AMED.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMED's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AMED Guru Trades in Q2 2016

Pioneer Investments 52,747 sh (New)
Jim Simons 633,001 sh (+0.33%)
Steven Cohen Sold Out
RS Investment Management 801,563 sh (-0.06%)
Joel Greenblatt 51,565 sh (-77.55%)
» More
Q3 2016

AMED Guru Trades in Q3 2016

Pioneer Investments Sold Out
Jim Simons 369,401 sh (-41.64%)
Joel Greenblatt 5,938 sh (-88.48%)
» More
Q4 2016

AMED Guru Trades in Q4 2016

Joel Greenblatt Sold Out
Jim Simons 262,300 sh (-28.99%)
» More
Q1 2017

AMED Guru Trades in Q1 2017

Jim Simons 24,800 sh (-90.55%)
» More
» Details

Insider Trades

Latest Guru Trades with AMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:NYSE:SEM, NYSE:AMN, NYSE:THC, NAS:SCAI, OTCPK:LTGHY, NAS:LPNT, NAS:TVTY, NYSE:CYH, NAS:LHCG, NAS:SGRY, NYSE:CHE, NAS:AFAM, NYSE:USPH, NAS:PRSC, NAS:ADUS, OTCPK:MFCSF, NAS:BIOS, NYSE:CCM, NYSE:AAC, NAS:ACHC » details
Traded in other countries:ADY.Germany,
Headquarter Location:USA
Amedisys Inc is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The Company's operations include servicing patients through its segments home health and hospice.

Amedisys Inc was incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The operations involve servicing patients through its three reportable business segments: home health, hospice and personal care. The home health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Personal care segment provides patients assistance with the essential activities of daily living. Individuals with a terminal illness such as heart disease, pulmonary disease, dementia, Alzheimers, HIV/AIDS or cancer may be eligible for hospice care. The Company operates 41 home health care centers and five hospice care centers with care centers servicing the same markets, sold 19 home health care centers and one hospice care center and closed 10 home health care centers. The Company's operations are regulated by Federal, state and local authorities.

Top Ranked Articles about Amedisys Inc

Amedisys to Present at May and June Healthcare Conferences
Amedisys Unveils New Logo, Signifying Its Transformation
Amedisys Announces First Quarter 2017 Earnings Release and Conference Call Date
Amedisys Announces Definitive Agreement to Acquire East Tennessee Personal Care Service
Amedisys to Present at the 27th Annual Oppenheimer Healthcare Conference
BATON ROUGE, La., March 13, 2017 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 27th Annual Oppenheimer Healthcare Conference in New York City, NY on Tuesday, March 21, 2017.The presentation will begin at 2:45 p.m. Eastern Time.  To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com.About Amedisys   Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
Contact:
Amedisys, Inc.
David Castille
Managing Director, Finance
225.299.3665
[email protected]

Read more...
Amedisys Announces Definitive Agreement to Acquire Six Home Health and Hospice Care Centers from Tenet Healthcare

BATON ROUGE, La., March 01, 2017 (GLOBE NEWSWIRE) --  Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home health care, hospice and personal care companies, today announced that it has signed a definitive agreement to acquire Tenet Healthcare’s (:THC) home health and hospice operations in Arizona, Illinois, Massachusetts and Texas.
“This acquisition gives Amedisys an incredible opportunity to continue our goal of providing high-quality post-acute services in key markets,” stated President and Chief Executive Officer Paul Kusserow. “We look forward to the opportunity to work with Tenet in these markets to improve the delivery of care and management of patients across the care continuum.” “Amedisys shares our commitment to serving patients, employees and the community,” stated Trevor Fetter, Chairman and Chief Executive Officer of Tenet Healthcare. “We are transferring these local operations of healthcare service providers to Amedisys so that high quality home health and hospice services will continue to be available within the communities they serve.” Since December 2015, Amedisys has announced six acquisitions, deploying approximately $125 million in capital and contributing approximately $145 million in revenue.  Forward-Looking Statements: When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 16,000 employees, in 420 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.  About Tenet Healthcare
Tenet Healthcare Corporation is a diversified healthcare services company with 130,000 employees united around a common mission: to help people live happier, healthier lives. Through its subsidiaries, partnerships and joint ventures, including United Surgical Partners International, the company operates 80 general acute care hospitals, 20 short-stay surgical hospitals and approximately 470 outpatient centers in the United States, as well as nine facilities in the United Kingdom. Tenet’s Conifer Health Solutions subsidiary provides technology-enabled performance improvement and health management solutions to hospitals, health systems, integrated delivery networks, physician groups, self-insured organizations and health plans. For more information, please visit www.tenethealth.com
Kendra Kimmons 
Managing Director of Communications 
225-299-3708 
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 43.89
AMED's PE Ratio is ranked lower than
76% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. AMED: 43.89 )
Ranked among companies with meaningful PE Ratio only.
AMED' s PE Ratio Range Over the Past 10 Years
Min: 4.65  Med: 16.96 Max: 79.39
Current: 43.89
4.65
79.39
Forward PE Ratio 28.90
AMED's Forward PE Ratio is ranked lower than
82% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 18.73 vs. AMED: 28.90 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 43.89
AMED's PE Ratio without NRI is ranked lower than
76% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 28.00 vs. AMED: 43.89 )
Ranked among companies with meaningful PE Ratio without NRI only.
AMED' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.65  Med: 16.98 Max: 77.36
Current: 43.89
4.65
77.36
Price-to-Owner-Earnings 1705.69
AMED's Price-to-Owner-Earnings is ranked lower than
99.99% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 27.48 vs. AMED: 1705.69 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMED' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.12  Med: 19.66 Max: 1711.69
Current: 1705.69
4.12
1711.69
PB Ratio 4.20
AMED's PB Ratio is ranked lower than
66% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 2.65 vs. AMED: 4.20 )
Ranked among companies with meaningful PB Ratio only.
AMED' s PB Ratio Range Over the Past 10 Years
Min: 0.5  Med: 2.08 Max: 4.22
Current: 4.2
0.5
4.22
PS Ratio 1.37
AMED's PS Ratio is ranked higher than
61% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. AMED: 1.37 )
Ranked among companies with meaningful PS Ratio only.
AMED' s PS Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.79 Max: 1.9
Current: 1.37
0.19
1.9
Price-to-Free-Cash-Flow 31.78
AMED's Price-to-Free-Cash-Flow is ranked lower than
70% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. AMED: 31.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMED' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.01  Med: 10.89 Max: 58
Current: 31.78
3.01
58
Price-to-Operating-Cash-Flow 26.26
AMED's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 14.15 vs. AMED: 26.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMED' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.02  Med: 6.53 Max: 30.83
Current: 26.26
2.02
30.83
EV-to-EBIT 25.39
AMED's EV-to-EBIT is ranked lower than
69% of the 292 Companies
in the Global Medical Care industry.

( Industry Median: 18.39 vs. AMED: 25.39 )
Ranked among companies with meaningful EV-to-EBIT only.
AMED' s EV-to-EBIT Range Over the Past 10 Years
Min: -178.9  Med: 7.5 Max: 2214.4
Current: 25.39
-178.9
2214.4
EV-to-EBITDA 20.45
AMED's EV-to-EBITDA is ranked lower than
71% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 13.46 vs. AMED: 20.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.5  Med: 7 Max: 65.5
Current: 20.45
-7.5
65.5
Current Ratio 1.32
AMED's Current Ratio is ranked lower than
56% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. AMED: 1.32 )
Ranked among companies with meaningful Current Ratio only.
AMED' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.01 Max: 2.88
Current: 1.32
0.33
2.88
Quick Ratio 1.32
AMED's Quick Ratio is ranked higher than
50% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. AMED: 1.32 )
Ranked among companies with meaningful Quick Ratio only.
AMED' s Quick Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.01 Max: 2.85
Current: 1.32
0.31
2.85
Days Sales Outstanding 43.20
AMED's Days Sales Outstanding is ranked lower than
52% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. AMED: 43.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.1  Med: 37.17 Max: 54.01
Current: 43.2
30.1
54.01
Days Payable 12.69
AMED's Days Payable is ranked lower than
81% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 40.41 vs. AMED: 12.69 )
Ranked among companies with meaningful Days Payable only.
AMED' s Days Payable Range Over the Past 10 Years
Min: 8.33  Med: 12.25 Max: 16.02
Current: 12.69
8.33
16.02

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
AMED's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. AMED: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.8  Med: -8.9 Max: 8.1
Current: -1.1
-47.8
8.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.21
AMED's Price-to-Tangible-Book is ranked lower than
90% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 3.76 vs. AMED: 14.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AMED' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2  Med: 4.45 Max: 120.46
Current: 14.21
0.2
120.46
Price-to-Intrinsic-Value-Projected-FCF 2.77
AMED's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
63% of the 89 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. AMED: 2.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMED' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.38 Max: 86
Current: 2.77
0
86
Price-to-Median-PS-Value 1.75
AMED's Price-to-Median-PS-Value is ranked lower than
76% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. AMED: 1.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMED' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.63 Max: 2.6
Current: 1.75
0
2.6
Price-to-Peter-Lynch-Fair-Value 0.73
AMED's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 2.13 vs. AMED: 0.73 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMED' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.72 Max: 3.24
Current: 0.73
0
3.24
Price-to-Graham-Number 5.27
AMED's Price-to-Graham-Number is ranked lower than
92% of the 123 Companies
in the Global Medical Care industry.

( Industry Median: 2.35 vs. AMED: 5.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
AMED' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0  Med: 2.41 Max: 11.17
Current: 5.27
0
11.17
Earnings Yield (Greenblatt) % 3.94
AMED's Earnings Yield (Greenblatt) % is ranked lower than
60% of the 334 Companies
in the Global Medical Care industry.

( Industry Median: 4.98 vs. AMED: 3.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMED' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 9.1 Max: 32.8
Current: 3.94
0.1
32.8
Forward Rate of Return (Yacktman) % 33.82
AMED's Forward Rate of Return (Yacktman) % is ranked higher than
90% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. AMED: 33.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMED' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7  Med: 40.8 Max: 109.3
Current: 33.82
7
109.3

More Statistics

Revenue (TTM) (Mil) $1,459
EPS (TTM) $ 1.36
Beta1.45
Short Percentage of Float14.91%
52-Week Range $34.58 - 61.39
Shares Outstanding (Mil)33.67

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,540 1,630
EPS ($) 2.07 2.38
EPS without NRI ($) 2.07 2.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for AMED

Headlines

Articles On GuruFocus.com
Amedisys to Present at May and June Healthcare Conferences May 09 2017 
Amedisys Unveils New Logo, Signifying Its Transformation May 03 2017 
Amedisys Announces First Quarter 2017 Earnings Release and Conference Call Date Apr 24 2017 
Amedisys Announces Definitive Agreement to Acquire East Tennessee Personal Care Service Mar 31 2017 
Amedisys to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 13 2017 
Amedisys Announces Definitive Agreement to Acquire Six Home Health and Hospice Care Centers from Ten Mar 01 2017 
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 

More From Other Websites
CMS Rating for Amedisys Home Health Centers Climbs to Average of 4.03 Stars May 25 2017
Thinly Traded Health Care Stock Tries To Resuscitate New Breakout May 24 2017
Amedisys to Present at May and June Healthcare Conferences May 09 2017
Edited Transcript of AMED earnings conference call or presentation 3-May-17 3:00pm GMT May 05 2017
Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark May 03 2017
Amedisys Unveils New Logo, Signifying Its Transformation May 03 2017
Amedisys tops Street 1Q forecasts May 02 2017
Amedisys Reports First Quarter 2017 Financial Results May 02 2017
Healthcare Q1 Earnings Slated on May 2: AET, HCA & More May 01 2017
ETFs with exposure to Amedisys, Inc. : April 25, 2017 Apr 25 2017
Amedisys Announces First Quarter 2017 Earnings Release and Conference Call Date Apr 24 2017
Amedisys (AMED) Poised on Strong Home Health, Risks Remain Apr 05 2017
Amedisys to Buy East Tennessee to Expand in Personal Care Apr 03 2017
Blog Coverage Amedisys Acquires East Tennessee Personal Care Service to Expand its Operations in... Apr 03 2017
Amedisys Announces Definitive Agreement to Acquire East Tennessee Personal Care Service Mar 31 2017
Amedisys to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 13 2017
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay Mar 03 2017
Amedisys, Inc. :AMED-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Tenet Healthcare (THC) to Divest Operations to Amedisys Mar 02 2017
Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)